Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
PR Newswire - Mon Aug 05, 7:01AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced the official launch of its business, operational and development activities as the Company unveils enhancements to its clinically proven oral peptide delivery platform, Peptelligence(TM), that extend the technology to small molecule therapeutics. Enteris recently acquired the Peptelligence(TM) platform, along with proven nasal delivery technology and a recombinant manufacturing process for therapeutically relevant peptides, from Unigene Laboratories, Inc.